Replies to post #438394 on Anavex Life Sciences Corp (AVXL)

[Bourbon_on_my_cornflakes]

Peer review wont help the stock, PW.

only NDA filings will convince the market that AVXL might have something.

Remember we are going for FDA market approval, not tenure.

[Steady_T]

The problem with that theory is Anavex can not control when the peer review paper will be published.
Generally the authors will be notified in advance of when the paper is going to be published. So perhaps Anavex could work that angle.

Releasing TLD can be done in advance of the PR paper. The PR would likely not be as in depth as it would be after the paper is published, but then afterwards the info would already be out there.

[attilathehunt]

What you say makes perfect sense...Unfortunately, Chris doesn't appear to think like the rest of us...

Maybe we will see a change. fingers crossed.

[tredenwater2]

2) To minimize that threat, would Anavex then time the Rett release to a period slightly before the peer review paper on the Alzheimer's P2b/3 trail results, thus establishing a higher value for Anavex?

How about just the opposite? Perhaps they are waiting for the peer review on AD and as soon as that is released all the while they are “cleaning” up RS TLD. In other words proving it works for AD (from a third party) and that it works for Rare diseases such as Rett Syndrome…. and everything in between.

Again folks this is not an Alzheimer’s drug or a Rett Syndrome only drug, this has the potential through genomic testing and AI to PROVE who is responding and by how much leading i to a prophylactic drug trial “system” like a basket trial. This is the “front end taking more time so the back end is faster.” (Paraphrased)

Just a couple more “t’” to cross and a few more “i’s” to dot and we are at the finish line for our first of multiple NDA submittals imo.